Key result
This statement reviews sex-specific data on the safety and efficacy of contemporary percutaneous coronary intervention and adjunctive pharmacotherapy in women.
Why the study?
What are the sex-specific data on the safety and efficacy of contemporary interventional therapies in women?
What are the sex-specific data on the safety and efficacy of contemporary interventional therapies in women?
This statement highlights the underutilization of PCI in women and reviews sex-specific data on the safety and efficacy of interventional therapies.
Answers are grounded in this paper and cite their sources.
Highlights potential inequity in PCI use among women; leaves open optimal sex-specific strategies pending dedicated trials.
More than 1.2 million percutaneous coronary interventions are performed annually in the United States, with only an estimated 33% performed in women, despite the established benefits of percutaneous coronary intervention and adjunctive pharmacotherapy in reducing fatal and nonfatal ischemic complications in acute myocardial infarction and high-risk acute coronary syndromes. This statement reviews sex-specific data on the safety and efficacy of contemporary interventional therapies in women.
No takes yet. Share an insight, caveat, or question.
Lansky et al. (2005) conducted a review in Acute myocardial infarction and high-risk acute coronary syndromes. Percutaneous coronary intervention and adjunctive pharmacotherapy was evaluated. This statement reviews sex-specific data on the safety and efficacy of contemporary percutaneous coronary intervention and adjunctive pharmacotherapy in women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: